BioSpace News Archive

AbbVie announced it will present 29 abstracts during the 2023 Digestive Disease Week Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.

Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA.

BeiGene announced the China National Medical Products Administration approved four applications for BRUKINSA, the company’s Bruton’s tyrosine kinase inhibitor, including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström’s macroglobulinemia, and two Supplemental Applications for conversions from conditional approval to regular approval.

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the presentation of clinical and preclinical data for IMU-856.

Philipp von Hugo, member of the board of directors of Immunovia AB, has at his own request notified his resignation from the Board of Directors of the Company and therefore declines re-election at annual general meeting on 26 May 2023.

Sight Sciences, Inc. announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved MIGS procedures in patients with mild stage glaucoma.